Brief: Genmab Announces Phase 3 Epcore Clinical Trial Results

Genmab A/S

07/08/2025 15:35

Aug 7 (Reuters) - Genmab A/S GMAB.CO:

GENMAB ANNOUNCES PHASE 3 EPCORE® FL-1 CLINICAL TRIAL MET DUAL PRIMARY ENDPOINTS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE  DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL RESPONSE RATE

FDA ACCEPTS PRIORITY REVIEW FOR EPCORITAMAB PLUS R(2)

STUDY MEETS ENDPOINTS, REDUCES RISK OF PROGRESSION OR DEATH BY 79%

Source text: ID:nGNE2D8g7V

Further company coverage: GMAB.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))